Update on the COVID-19 pandemic

Information regarding COVID-19 is in constant change, as is the situation regarding vaccination and prioritization for immune-compromised individuals.

If you have any COVID-19-related questions, we’ve created a specific COVID section on our website that can be accessed by clicking here or by selecting the “News & Events” tab from our homepage. In this section, you’ll find the latest news and information about the pandemic in Canada from trustworthy and reliable sources.

Any specific questions that you may have regarding the COVID-19 vaccination, delays between vaccine dosing, and prioritization within your province are best answered by your healthcare team. They’re the ones who know you and your particular situation and are therefore in a position to best address your unique concerns.

Created by, and entirely focused on, Canadians impacted by myeloma, Myeloma Canada is the only national charitable organization committed to providing you with the most up-to-date and reliable information on myeloma. Some of the ways we do this is through our monthly e-newsletter, “Myeloma Matters”, as well as through our social media platforms.

Please don’t hesitate to contact us at contact@myeloma.ca or toll-free at 1-888-798-5771 with any questions regarding our programs and services.


Make a donation

InfoSessions & Webinars — Wednesday, July 14, 2021, 16:00 - 17:00

About MGUS and Smouldering Multiple Myeloma

About MGUS and Smouldering Multiple Myeloma

Wednesday, July 14, 2021
4:00 – 5:00 pm EST

Register Now!

Monoclonal gammopathy of undetermined significant (MGUS), smouldering multiple myeloma (SMM) and active multiple myeloma are a group of conditions and diseases that fall under the category of plasma cell disorders. As the name suggests, plasma cell disorders affect plasma cells – a type of white blood cell (WBC) produced in the bone marrow.

MGUS is the earliest state of myeloma and is often referred to as a pre-cursor condition. SMM is the intermediate state between MGUS and active myeloma. This InfoWebinar will discuss MGUS, SMM, and research advances in both conditions.


Presented by: 

Dr Omar Nadeem
Jerome Lipper Multiple Myeloma Center
Clinical Director, Myeloma Cellular Therapies Program
Dana-Farber Cancer Institute
Instructor in Medicine, Harvard Medical School
Boston, MA

Join us online from the comfort of your own home! All you need is a computer, tablet or smart phone and an internet connection. Click here to register for the webinar.